Universal vaccine against respiratory syncytial virus A and B subtypes

Collection with item attached
2017
Item details URL
http://open-repository.kisti.re.kr/cube/handle/open_repository/486737.do
DOI
10.1371/journal.pone.0175384
Title
Universal vaccine against respiratory syncytial virus A and B subtypes
Description
This research was supported by Basic Science Research Program throughthe National Research Foundation of Korea(NRF) funded by the Ministry ofEducation, Science and Technology (NRF-2013R1A1A2060008) and by a grantof Korean Health Technology R& D Project, the Ministry of Health &Welfare (HI13C0826), Republic of Korea. The funders had no role in studydesign, data collection and analysis, decision to publish, orpreparation of the manuscript.
abstract
Respiratory syncytial virus (RSV) is a major cause of acute lower respiratory tract infection in infants, young children, and the elderly. Two subtypes of RSV, A and B, circulate alternately at 1-2-year intervals during epidemics. The attachment glycoprotein (G protein) of RSV is one of the major targets for immune responses. In this study, we generated a recombinant fusion protein, GcfAB, which consists of the central regions (a. a. residues 131-230) of the G proteins of both RSV A (A2 strain) and B (B1 strain) subtypes, and investigated immunogenicity, protective efficacy, and immunopathology. We immunized mice with GcfAB plus cholera toxin as a mucosal adjuvant via intranasal ( -IN) or sublingual (SL) routes. The IN group showed higher levels of RSV G-specific antibody responses, including serum IgG and mucosal IgA, compared with the SL group. On the contrary, more vigorous RSV G-specific CD4(+) T-cell responses were elicited in the SL group than in the IN group after RSV-A but not RSV-B viral challenge. Furthermore, the SL group showed more pulmonary eosinophil recruitment and body weight loss than did the IN group after RSV-A challenge. Both IN and SL immunization with GcfAB provided potential protection against both subtypes of infections. Together, these results suggest that vaccination with GcfAB via an IN route could be a universal vaccine regimen preventing both RSV A and B infections.
provenance
Made available in Cube on 2018-09-28T16:15:35Z (GMT). No. of bitstreams: 0
language
English
author
Lee, Jeong-Yoon
Chang, Jun
orcid
CHANG, JUN/0000-0002-8423-5987
accessioned
2018-09-28T16:15:35Z
available
2018-09-28T16:15:35Z
issued
2017
citation
PLOS ONE(12): 4
issn
1932-6203
uri
http://open-repository.kisti.re.kr/cube/handle/open_repository/486737.do
Funder
보건복지부
Funding Program
감염병위기대응기술개발
Project ID
1465023847
Jurisdiction
Rep.of Korea
Project Name
Development and evaluation of vaccine efficacy
rights
openAccess
type
article


Files in This Item

There are no attached files.